Approval · Notice of Compliance 4847 · 2004
TEVETEN: Notice of Compliance 4847
Issued August 5, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 4847
- Date
- August 5, 2004
- Company
- Solvay Pharma Inc.Saint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revisions to the dosage and administration section of the product monograph
- Therapeutic class
- Angiotensin ii receptor (at1) antagonist
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVETEN | Not yet assigned | — |
Medicinal ingredients
- EPROSARTAN MESYLATE 400 MG per TAB
- EPROSARTAN MESYLATE 600 MG per TAB